Contraception
Volume 79, Issue 4 , Pages 272-281 , April 2009

Profile of the progesterone derivative chlormadinone acetate — Pharmocodynamic properties and therapeutic applications

Received 6 May 2008 ,Revised 27 October 2008 ,Accepted 28 October 2008.

References 

  1. Liu Z, Auboeuf D, Wong J, et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc Natl Acad Sci U S A. 2002;99:7940–7944
  2. Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51:188–215
  3. Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–S16
  4. Stanczyk FZ. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocr Metab Disord. 2002;3:211–224
  5. Ng EH, Miao B, Cheung W, Ho PC. A randomised comparison of side effects and patient inconvenience of two vaginal progesterone formulations used for luteal support in in vitro fertilisation cycles. Eur J Obstet Gynecol Reprod Biol. 2003;111:50–54
  6. Dansuk R, Unal O, Karsidag YK, Turan C. Evaluation of the effects of various gestagens on insulin sensitivity, using homeostatic model assessment, in postmenopausal women on hormone replacement therapy. Gynecol Endocrinol. 2005;20:1–5
  7. Chang TC, Chen M, Lien YR, Chen RJ, Chow SN. Comparison of the difference in histopathology and cell cycle kinetics among the postmenopausal endometrium treated with different progestins in sequential-combined hormone replacement therapy. Menopause. 2003;10:172–178
  8. Warren MP, Shantha S. Uses of progesterone in clinical practice. Int J Fertil Women's Med. 1999;44:96–103
  9. Pelissier C, Maroni M, Yaneva H, Brin S, Peltier-Pujol F, Jondet M. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. Maturitas. 2001;40:85–94
  10. Fugère P, Percival-Smith RK, Lussier-Cacan S, Davignon J, Farquhar D. Cyproterone acetate/ethinyl estradiol in the treatment of acne. A comparative dose–response study of the estrogen component. Contraception. 1990;42:225–234
  11. Sahin Y, Bayram F, Kelestimur F, Muderris I. Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism. J Endocrinol Invest. 1998;21:348–352
  12. Vegetti W, Testa G, Maggioni P, Motta T, Falsetti L, Crosignani PG. An open randomized comparative study of an oral contraceptive containing ethinyl estradiol and cyproterone acetate with and without the GnRH analogue goserelin in the long-term treatment of hirsutism. Gynecol Obstet Invest. 1996;41:260–268
  13. Martinez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Reprod Health Care. 2007;12:97–106
  14. Winkler UH, Daume E, Sudik R, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care. 1999;4:145–154
  15. Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76:342–347
  16. Worret I, Arp W, Zahradnik H, Andreas J, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203:38–44
  17. Paris F, Rabeolina F, Balaguer P, Bacquet A, Sultan C. Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecol Endocrinol. 2007;23:193–197
  18. Sator PG, Schmidt JB, Honigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study. Dermatology. 2003;206:241–248
  19. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception. 2006;73:23–29
  20. Tan JK, Degreef H. Oral contraceptives in the treatment of acne. Skin Therapy Lett. 2001;6:1–3
  21. Druckmann R. Long-term use of progestogens — getting the balance right: Molecular biology and the endometrium. Gynecol Endocrinol. 2007;23(Suppl 1):53–61
  22. Greer JB, Modugno F, Allen GO, Ness RB. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731–740
  23. Kuhl H, Jung-Hoffmann C. In: Pharmakologie der Gestagene. Thieme: Kontrazeption; 1999;p. 28–31
  24. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs. 2003;63:463–492
  25. Kuhl H. Chemie und Pharmakologie von Chlormadinonacetat. In:  Loch EG,  Schramm G editor. Chlormadinonacetat bei Androgenisieringserscheinungen. Stuttgart: Schattauer Verlag; 1995;p. 1–24
  26. Larsson-Cohn U, Johansson ED, Wide L, Gemzell C. Effects of continuous daily administration of 0.5 mg of chlormadinone acetate on the plasma levels of progesterone and on the urinary excretion of luteinizing hormone and total oestrogens. Acta Endocrinol (Copenh). 1970;63:705–716
  27. Saunders DM, Marcus SL, Saxena BB, Beling CG, Connell EB. Effect of daily administration of 0.5 mg. of chlormadinone acetate on plasma levels of follicle-stimulating hormone, luteinizing hormone, and progesterone during the menstrual cycle. Fertil Steril. 1971;22:332–344
  28. Voigt W, Fernandez EP, Hsia SL. Transformation of testosterone into 17 beta-hydroxy-5 alpha-androstan-3-one by microsomal preparations of human skin. J Biol Chem. 1970;245:5594–5599
  29. Terouanne B, Paris F, Servant N, Georget V, Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocrinol. 2002;198:143–147
  30. Dugwekar YG, Narula RK, Laumas KR. Disappearance of 1 alpha-3H-chlormadinone acetate from the plasma of women. Contraception. 1973;7:27–45
  31. Gallegos AJ, Gonzalez-Diddi M, Merino G, Martinez-Manautou J. Tissue localization of radioactive chlormadinone acetate and progesterone in the human. Contraception. 1970;1:151–161
  32. Chassard D, Legallicier P, Dib M. The relative pharmacokinetics of two oral formulations of chlormadinone acetate: Luteran 5 mg and Luteran tablet 10 mg. Therapie. 2003;58:127–131
  33. Dugwekar YG, Narula RK, Laumas KR. Distribution of 1α-3H-chlormadinone acetate in the reproductive tract of women. Contraception. 1973;4:313–325
  34. Terlinden R, Uragg H, Gohler K, Kneip C. Pharmacokinetics of chlormadinone acetate following single and multiple oral dosing of chlormadinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination and clearance of a single dose of radiolabeled chlormadinone acetate. Contraception. 2006;74:239–244
  35. Honma S, Iwamura S, Iizuka K, Kambegawa A, Shida K. Identification and anti-androgenic activity of the metabolites of 17alpha-acetoxy-6-chloropregna-4,6-diene-3,20-dione (chlormadinone acetate) in the rat, rabbit, dog and man. Chem Pharm Bull (Tokyo). 1977;25:2019–2031
  36. Kuhl H. Pharmacology of progestogens. Basics aspects — progesterone derivates. Menopause Review. 2001;6:9–17
  37. Rozenbaum H. Les Progestatifs. Paris: Eska; 2002;
  38. Pelissier C, Caby J. Contraception des femmes à hauts risques vasculaires et métaboliques: essai d'un dérivé de la 17 0H progestérone. Gynécologie. 1983;34:131–138
  39. Elkik F, Mauvais-Jarvis P. The role of progesterone and progestins in hydroelectrolytic metabolism (author's transl). Nouv Presse Med. 1980;9:35–38
  40. Spellacy WN, Newton RE, Buhi WC, Birk SA. Lipid and carbohydrate metabolic studies after one year of megestrol acetate treatment. Fertil Steril. 1976;27:157–161
  41. Conard J, Samama M. The effects of progestins on coagulation. In:  Bardin CW,  Milgrom E,  Mauvais-Jarvis P editor. Progesterone and Progestins. New York: Raven Press; 1983;p. 447–452
  42. Conard J, Cazenave B, Samama M, Horellou MH, Zorn JR, Neau C. At III content and antithrombin activity in oestrogen-progestogen and progestogen-only treated women. Thromb Res. 1980;18:675–681
  43. Wynn V, Niththyananthan R. The effect of progestins in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol. 1982;142:766–771
  44. Pelissier C, Basdevant A, Conard J, Egloff M, Husson T, Guyenne TT. Progestogen contraception using chlormadinone acetate in women presenting high vascular risk. (A gynecoendocrine, metabolic and vascular study.). Contracept Fertil Sex (Paris). 1987;15:45–54
  45. Pelissier C, Basdevant A, Conard J, et al. Administration prolongée d'acétate de chlormadinone: effets métaboliques, tensionnels et hormonaux. Gynécologie. 1991;42:79–86
  46. Pelissier C. Tolérance clinique, métabolique et vasculaire de l'association 17β-estradiol et acétate de chlormadinone chez la femme ménopausée normale ou à risque artériel. Etude prospective contrôlée, randomisée, à long terme (18 mois). Rev Prat Gynecol Obstet. 1999;29:35–40
  47. Bazin B, Thevenot R, Bursaux C, Paris J. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary–ovarian function in women. Br J Obstet Gynaecol. 1987;94:1199–1204
  48. Knobil E, Hotchkiss J. The menstrual cycle and its neuroendocrine control. In:  Knobil E,  Neill J editor. The Physiology of Reproduction. New York: Raven Press; 1994;p. 711–749
  49. Couzinet B, Young J, Brailly S, Chanson P, Thomas JL, Schaison G. The antigonadotropic activity of progestins (19-nortestosterone and 19-norprogesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab. 1996;81:4218–4223
  50. Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab. 1999;84:4191–4196
  51. Warembourg M, Deneux D, Krieger M, Jolivet A. Progesterone receptor immunoreactivity in aromatic l-amino acid decarboxylase-containing neurons of the guinea pig hypothalamus and preoptic area. J Comp Neurol. 1996;367:477–490
  52. Pelissier C, Blacker C, Feinstein MC, Cournot A, Denis C. Antiovulatory action of chlormadinone acetate. Contracept Fertil Sex (Paris). 1994;22:37–40
  53. Young J, Brailly S, Chassard D, Chanson P. Activité antogonadotrope de l'acétate de chlormadinone. Rev Prat Gynecol Obstet. 2000;40:33–39
  54. Chassard D, Schatz B. The antigonadotropic activity of chlormadinone acetate in reproductive women. Gynecol Obstet Fertil. 2005;33:29–34
  55. Contreras CM, Azamar-Arizmendi G, Saavedra M, Hernandez-Lozano M. A five-day gradual reduction regimen of chlormadinone reduces premenstrual anxiety and depression: a pilot study. Arch Med Res. 2006;37:907–913
  56. Cronje WH, Studd JW. Premenstrual syndrome and premenstrual dysphoric disorder. Prim Care 2002;29:1-12, v.
  57. Druckmann R. The role of progestins in puberty and adolescence. Zentralbl Gynakol. 1997;119(Suppl):25–33
  58. Dewhurst JC. Menstrual disorders in the adolescent. In:  Symonds EM,  Zuspan FP editor. Practical Pediatric and Adolescent Gynecology. New York: Dekker; 1980;p. 144–157
  59. Arowojolu AO, Gallo MF, Grimes DA, Garner SE. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2004;CD004425
  60. Sitruk-Ware R, Husmann F, Thijssen JH, et al. Role of progestins with partial antiandrogenic effects. Climacteric. 2004;7:238–254
  61. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest. 2002;22:221–231
  62. Runnebaum B, Rabe T. Gynäkologische Endokrinologie. Berlin: Springer-Verlag; 1994;
  63. Conard J, Plu-Bureau G, Bahi N, Horellou MH, Pelissier C, Thalabard JC. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception. 2004;70:437–441
  64. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  65. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet. 1997;349:83–88
  66. Farmer RDT, Preston TD. The risk of thromboembolism associated with low-dose estrogen oral contraceptives. J Obstet Gynaecol. 1995;15:195–200
  67. Gerstmann BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol. 1991;133:32–37
  68. Jick H, Jick S, Gurewich V, Myers M, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589–1593
  69. Newburger J, Goldzieher JW. Pharmacokinetics of ethynyl estradiol: a current view. Contraception. 1985;32:33–44
  70. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol. 1987;156:199–203
  71. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  72. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) — an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008;77:337–343
  73. Zahradnik H, Goldberg J, Andreas J. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–109
  74. Pariser S. Women and mood disorders. Menarche to menopause. Ann Clin Psychiatry. 1993;5:249–254
  75. Sanders S, Graham C, Bass J, Bancroft J. A prospective study of the effects of oral contraceptives on sexuality and well-being and their relationship to discontinuation. Contraception. 2001;64:51–58
  76. Eriksson E, Sundblad C, Lisjo P, Modigh K, Andersch B. Serum levels of androgens are higher in women with premenstrual irritability and dysphoria than in controls. Psychoneuroendocrinology. 1992;17:195–204
  77. Rapkin A. A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. Psychoneuroendocrinology. 2003;28(Suppl 3):39–53
  78. Garcia-Becerra R, Cooney AJ, Borja-Cacho E, Lemus AE, Perez-Palacios G, Larrea F. Comparative evaluation of androgen and progesterone receptor transcription selectivity indices of 19-nortestosterone-derived progestins. J Steroid Biochem Mol Biol. 2004;91:21–27
  79. Bakry S, Merhi ZO, Scalise TJ, Mahmoud MS, Fadiel A, Naftolin F. Depot-medroxyprogesterone acetate: an update. Arch Gynecol Obstet. 2008;278:1–12
  80. Kaunitz AM. Current concepts regarding use of DMPA. J Reprod Med. 2002;47:785–789
  81. Wysocki S. A survey of American women regarding the use of oral contraceptives and weight gain. Int J Gynecol Obstet. 2000;70:114;[Abstract]
  82. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2006;CD003987
  83. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2003;CD003987
  84. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives containing 0.03 mg ethinylestradiol and either 2 mg chlormadinone acetate or 0.15 mg desogestrel on lipid, hormone and metabolic parameters. Contraception. 2009;79:15–23

☆ This review was sponsored by Grünenthal GmbH, Aachen, Germany.

PII: S0010-7824(08)00548-9

doi: 10.1016/j.contraception.2008.10.017

Contraception
Volume 79, Issue 4 , Pages 272-281 , April 2009

Article Tools

* Image Usage & Resolution